You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Arthritis

Golimumab for the treatment of psoriatic arthritis

  • Technology appraisal guidance
  • Reference number: TA220
  • Published:  27 April 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendation for further research
  • 7 Appraisal Committee members and NICE project team
  • 8 Sources of evidence considered by the Committee
  • Update information

6 Recommendation for further research

6.1

The Committee highlighted the importance of collecting further data within registries of patients receiving biological treatments for psoriatic arthritis to obtain information on long-term outcomes, including adverse events.


Next page 7 Appraisal Committee members and NICE project team Previous page 5 Implementation
Back to top